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Abstract: While prostate cancer is a common disease in men, it is uncommonly life-threatening. 
To better understand this phenomenon, tumor biologists have sought to elucidate the mechanisms 
that contribute to the development of virulent prostate cancer. The recent discovery that 
caveolin-1 (Cav-1) functions as an important oncogene involved in prostate cancer progression 
reflects the success of this effort. Cav-1 is a major structural coat protein of caveolae, specialized 
plasma membrane invaginations involved in multiple cellular functions, including molecular 
transport, cell adhesion, and signal transduction. Cav-1 is aberrantly overexpressed in human 
prostate cancer, with higher levels evident in metastatic versus primary sites. Intracellular Cav-1 
promotes cell survival through activation of Akt and enhancement of additional growth factor 
pro-survival pathways. Cav-1 is also secreted as a biologically active molecule that promotes 
cell survival and angiogenesis within the tumor microenvironment. Secreted Cav-1 can be 
reproducibly detected in peripheral blood using a sensitive and specific immunoassay. Cav-1 
levels distinguish men with prostate cancer from normal controls, and preoperative Cav-1 
levels predict which patients are at highest risk for relapse following radical prostatectomy 
for localized disease. Thus, secreted Cav-1 is a promising biomarker in identifying clinically 
significant prostate cancer.
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Introduction
Over the past decade, advances in basic tumor biology have influenced the approach to 
treating patients with prostate cancer. While research efforts have historically focused 
on the prostate cancer epithelial cell, there is growing evidence that interactions 
between the host tissue microenvironment and the cancer epithelial cell are critical 
for tumorigenesis.1 Understanding the bidirectional cancer cell-host interaction now 
dominates prostate cancer research. For example, prostate cancer epithelial cells 
preferentially metastasize to bone by acquiring osteomimetic properties that usurp 
normal bone homeostasis.2 Once in the bone, prostate cancer epithelial cells secrete 
soluble factors that act through both paracrine and autocrine mechanisms to promote 
cell survival and angiogenesis. This knowledge has led to novel treatment strategies 
that target the bone microenvironment (eg, with antiangiogenesis inhibitors) in addition 
to the epithelial cell (eg, with chemotherapy).
Despite this progress, however, novel biomarkers are needed to improve the ability 
to detect prostate cancer, predict prostate cancer lethality, and monitor response 
to therapy. Prostate-specific antigen (PSA) is the most widely used biomarker in 
prostate cancer management, but after two decades its value and appropriate use Cancer Management and Research 2010:2 112
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remain controversial.3,4 This has led to the development of 
additional biomarkers to compensate for, or improve upon, 
the limitations of PSA. Candidate prostate cancer biomarkers 
now broadly include circulating tumor cells, tumor-specific 
genetic changes (mutations, amplifications, deletions, 
translocations), epigenetic changes (DNA methylation, 
histone modifications, microRNAs), and protein changes 
(increased expression of oncogenic proteins, diminished 
expression of tumor suppressor proteins, production of soluble 
tumor-associated proteins).5–7 High-throughput technologies 
are also significantly impacting prostate cancer biomarker 
research, with the potential to provide comprehensive tumor 
“transcriptomes” (complete set of mRNAs expressed) and 
“proteomes” (complete set of proteins expressed).8
To date, however, few of these markers have made 
the transition from research to clinical practice. Most 
biomarkers are attractive in theory but fail to meet the 
required standards for a clinically useful test with respect 
to sensitivity/specificity, positive/negative predictive value, 
reproducibility, reliability, precision, accuracy, and validity. 
For these reasons, the development of a successful biomarker 
is as challenging as the development of a successful new 
drug, since both discovery platforms involve screening 
hundreds of candidates, discarding most, and validating 
only a select few.9 Given the reality of limited funding for 
translational research, limited patient tissue resources (blood, 
urine, biopsy specimens, etc), and limited time to meet critical 
patient needs, it is essential to prioritize development of the 
most promising biomarkers.10
For a number or years, our laboratory has been investigating 
the use of caveolin-1 (Cav-1) as a novel predictive biomarker 
for prostate cancer progression.11 Cav-1 is an important 
regulatory molecule involved in molecular transport and cell 
signaling.12 While normal prostate epithelia express minimal 
levels of Cav-1, prostate cancer cells abundantly overexpress 
Cav-1, both at the tissue level and as a secreted protein in 
sera that can be measured by enzyme-linked immunosorbent 
assay (ELISA).13 In contrast with PSA, detailed mechanis-
tic studies have shown that Cav-1 is linked to malignant 
characteristics of prostate cancer cells and alters the tissue 
microenvironment in a manner that promotes angiogenesis.14 
In this review, we discuss current concepts illustrating the 
need for novel biomarkers in prostate cancer and the potential 
for Cav-1 to fill this need.
Clinical features of prostate cancer
Prostate cancer is a major health care problem in the US. 
It is the most common noncutaneous malignancy and the 
second leading cause of cancer death in men. In 2009, it 
is estimated that 192,280 men will be newly diagnosed 
with prostate cancer and 27,360 men will die from the 
disease.15 The greatest risk factor for developing and 
dying from prostate cancer is increasing age.16,17 Thus, 
as life expectancies increase and death rates decrease, 
the burden of prostate cancer on patients, families, and 
society continues to grow.18 Other prostate cancer risk 
factors include race (African-American), family history, 
obesity, and hereditary susceptibility loci, including 
BRAC1/BRACA2.19–22
Prostate cancer is a biologically and clinically heterogeneous 
disease. While most men who live long enough eventually 
develop prostate cancer, only a minority will die from it. 
This is evidenced by a high incidence of occult malignancy 
in autopsy series of men who die from non-prostate cancer 
causes and in clinically normal prostates of men undergoing 
cystoprostatectomy for bladder cancer.23,24 These data illustrate 
two unique features of prostate cancer that distinguish it from 
other solid tumor types. First, untreated prostate cancer has 
a relatively prolonged natural history and is often indolent 
for 15 years or more before becoming life-threatening.25,26 
Second, longitudinal studies suggest that prostate cancer has 
the potential to be either clinically “significant” or clinically 
“insignificant” based on the likelihood that the cancer will 
threaten a person over the course of his natural lifetime.27 
For these reasons, it is critical to consider a patient’s age and 
comorbidities at the time of diagnosis, since the risk of mor-
bidity and mortality from non-prostate cancer illnesses also 
increases with age and may even exceed those from prostate 
cancer in older patients.25
For those patients with clinically significant disease, 
tumor progression occurs in a well-recognized anatomic pat-
tern.28 Tumors that are initially confined within the prostate 
gland first spread to locoregional lymph nodes (though not 
usually with radiographic enlargement) and then subsequently 
disseminate to distant organs, with a striking predilection for 
the skeleton.2 The discovery and application of hormone 
ablative therapy to patients with metastatic disease reveals 
that most tumors (90%) are initially responsive to castration 
but remain incurable because of the subsequent evolution of 
castrate-resistant disease. Thus, the greatest opportunity to 
cure patients with prostate cancer is through local therapy 
(surgery or radiation) for early-stage, small-volume, 
androgen-dependent, organ-confined disease. Fortunately, 
only a minority of patients ultimately develop metastatic 
castrate-resistant disease. To conceptualize the clinical 
heterogeneity evident during prostate cancer progression, Cancer Management and Research 2010:2 113
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patients are assigned to different “clinical disease states” 
to help structure treatment recommendations as well as the 
development of novel therapies and biomarkers.29,30
Prior to the discovery of PSA, most patients with 
prostate cancer were not diagnosed until they presented 
with clinical symptoms of advanced disease, such as bladder 
outlet obstruction or bony pain. These patients were rarely 
cured with available therapies. Following the widespread 
implementation of PSA screening in 1988, however, there 
has been a dramatic increase in the number of asymptomatic 
younger men detected with earlier-stage, localized disease.31 
This “stage-migration” phenomenon has been accompanied 
by a significant increase in the number of patients undergoing 
radical prostatectomy.32
The advent of PSA also influenced the development of 
a logical strategy to reduce morbidity and mortality from 
prostate cancer, by detecting clinically significant cancers 
at their earliest stage when they are androgen-dependent 
and organ-confined, because these tumors have the great-
est chance of being cured with local therapy (surgery or 
radiation).33,34 In support of this strategy, treatment of 
early-stage tumors with radical prostatectomy has been shown 
to improve survival when compared with watchful waiting 
in a randomized clinical trial.35 In this study, the majority of 
tumors were detected by digital rectal examination rather 
than PSA. Since tumors detected by PSA are generally of 
lower clinical stage than tumors detected by digital rectal 
examination (for example, comparing T1c versus T2 dis-
ease), one would predict that treatment of PSA-detected 
tumors would improve outcomes for men diagnosed with 
prostate cancer.
However, whether the practice of PSA screening and 
early therapeutic intervention has contributed to the decline 
in death rates from prostate cancer remains controversial. The 
recent publication of two large randomized screening trials 
(with greater than 250,000 patients) has not helped clarify 
the issue, given that one trial did not show a survival benefit 
(the Prostate, Lung, Colorectal and Ovarian Cancer Screen-
ing Trial [PLCO] in the US) while the other one did (the 
European Randomised Study of Screening for Prostate Cancer 
[ERSPC] trial in Europe).36,37 In the positive ERSPC trial, it 
was estimated that 1,410 men would need to be screened and 
48 treated to prevent one prostate cancer death during a 10-
year period. Thus, the benefits of screening come at a high 
cost with respect to the large number of patients that need to 
be screened, biopsied, and treated to prevent each death.
The success of the early diagnosis-early intervention 
strategy has arguably been hampered by the lack of accurate 
clinicopathologic, prognostic, and predictive biomarkers 
to distinguish reliably between clinically significant and 
insignificant disease. For example, because most early-stage 
cancers are statistically likely to be clinically insignificant, 
many patients are “overdiagnosed” and “overtreated” 
because they receive local therapy for tumors that would 
never have harmed them. Since local therapies carry some 
risk for morbidity (eg, incontinence, loss of potency), this 
has important implications for the patient who receives 
unnecessary treatment. Overtreatment, in conjunction with 
lead-time bias due to PSA screening (where survival appears 
longer because of diagnosis before the cancer is clinically 
evident), certainly dilute the survival benefit of treating 
early-stage disease.38
Conversely, some patients are “undertreated” because local 
therapies are not uniformly curative for clinically significant 
disease. Reasons for this include deficiencies in execution 
of the therapeutic modality (for example, inadequate tumor 
resection by an inexperienced surgeon), localized tumors with 
an aggressive biology that is not altered by local therapy, and 
undetectable micrometastases at the time of treatment. These 
“undertreated” patients also diminish the potential positive 
impact of local treatment on survival. As evidence for this, 
up to 35% of patients will experience a PSA relapse follow-
ing local therapy.39 These patients also suggest that efforts 
to improve local control and eradicate micrometastases (for 
example, by incorporating neoadjuvant or adjuvant therapy 
into local therapy) would benefit long-term patient out-
comes.39 Emerging data support this hypothesis, including 
the use of adjuvant radiation following radical prostatectomy 
for high-risk, node-negative tumors, immediate treatment 
with hormone ablation following radical prostatectomy and 
lymphadenectomy for node-positive disease, and the use of 
adjuvant hormone ablation following radiation therapy for 
high-risk disease.40–42
As the incidence of men diagnosed and treated for 
localized prostate cancer increases, so does the incidence of 
men presenting with PSA-only recurrent disease (in other 
words, no radiographic evidence for metastases). This sce-
nario poses a therapeutic dilemma for physicians and consid-
erable anxiety for patients. Remarkably, as experience with 
this disease state matures, it is becoming clear that PSA-only 
recurrences do not uniformly portend morbidity/mortality 
from the disease. For example, data from a large series of 
patients who underwent radical prostatectomy for localized 
disease showed that only approximately one-third of patients 
who experience a PSA relapse go on to develop metastases 
within 15 years and, for those who did, the median time to Cancer Management and Research 2010:2 114
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death was five years.43 These patients are generally offered 
hormone ablative therapy, commonly using an intermittent 
strategy.44
For patients with metastatic disease, the initial standard 
treatment approach is hormone ablative therapy for 
androgen-dependent disease.45 However, this therapy 
is not curative and most patients eventually develop 
castrate-resistant progression within 12 to 18 months.46 
Castrate-resistant prostate cancer is defined as progression 
when the serum testosterone level is 50 ng/dL.30 Even 
in the clinically castrate disease state, however, there is 
growing evidence that prostate cancer cells continue to rely 
on androgen receptor signaling by utilizing extragonadal 
sources of testosterone produced in the adrenal gland and 
by the tumor itself.47 Tumors in this clinical state continue 
to respond to secondary hormonal manipulations including 
ketoconazole, diethylstilbestrol, and abiraterone.48 When 
tumors truly become castrate-resistant, patients are offered 
docetaxel-based cytotoxic chemotherapy, which results in 
significant palliation of symptoms but only a modest pro-
longation in survival.49,50
In order to identify which prostate cancers require 
treatment and to improve existing therapies for those that 
do, there is a real sense of urgency among physicians and 
scientists to improve our ability to predict which prostate 
cancers are most virulent. This will require refinement of 
existing predictive and prognostic tools that are commonly 
employed by physicians to manage prostate cancer patients 
among different disease states. In this way, treatment will 
be applied only to patients who need it, while avoiding 
unnecessary treatment-related morbidity for those who 
do not. A major translational research effort is presently 
underway to address this need through the identification of 
novel biomarkers for prostate cancer.
Biomarkers for prostate cancer
A biomarker is defined as a characteristic that is measured 
and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a 
therapeutic intervention.51 Biomarkers can thus provide 
information about the biology and natural history of 
the patient’s disease (diagnostic/prognostic biomarker), the 
probability a patient will respond to a particular therapy 
(predictive biomarker), and “target engagement” by the 
therapy and modulation of the tumor phenotype in a clinically 
favorable manner (pharmacodynamic biomarker).52 There 
are four principal promises of biomarker research.10 First, 
biomarkers will improve current standards for defining 
disease by adding molecular analyses to more traditional 
criteria relying on patient symptoms and tissue pathology. 
Second, the clinical trials process will improve because 
biomarkers will provide “short-term” surrogate endpoints 
that substitute for traditional “long-term” endpoints such as 
time to disease recurrence and/or mortality from disease. 
Third, clinical care will improve based on the concept of 
personalized medicine – the idea that biomarkers will help 
physicians select therapies with the highest likelihood of 
success based on a patient’s unique host and tumor biology. 
Fourth, the drug discovery process will become more efficient 
(and thereby less expensive) because biomarkers will help 
identify the most promising candidate therapeutics worthy 
of further development.
The most widely used biomarker in prostate cancer 
diagnosis and management is serum PSA.4,53 PSA is an 
androgen-regulated, serine protease encoded as a member of 
the tissue kallikrein family located on chromosome 19q13.4. 
Its normal physiologic function is to liquefy seminal fluid. 
PSA is synthesized in normal prostate tissue, benign pros-
tatic hypertrophy, and in prostate cancer. The increase in 
serum PSA observed in prostate cancer patients is not due 
to increased expression of PSA on a cellular level per se, 
but rather tumor-associated disruption of normal prostate 
tissue architecture that leads to increased release of PSA into 
peripheral blood.54 PSA was first approved in 1986 by the 
Food and Drug Adminstration (FDA) to monitor response 
in patients treated for prostate cancer and subsequently as a 
diagnostic marker in 1994. Even at the time of its discovery, 
however, three inherent limitations of PSA as a biomarker 
were evident. First, PSA is not a prostate cancer specific 
antigen. Second, PSA does not reliably predict grade or 
stage of prostate cancer at diagnosis. Third, PSA reflects 
tumor volume but does not functionally contribute to the 
pathophysiology of tumor progression. Thus by itself, PSA 
does not distinguish clinically significant from insignificant 
prostate cancer. For these reasons, PSA is most useful as 
a predictive/prognostic tool when combined with other 
clinicopathologic parameters.
For patients with newly diagnosed prostate cancer, a 
combination of pretreatment PSA, Gleason score, and clinical 
stage have been incorporated into models to predict outcomes 
following radical prostatectomy or radiation therapy. 
Investigators at Johns Hopkins first used these three variables 
to predict the rate of finding disease that is not confined to the 
prostate at the time of surgery (by pathologic analysis of the 
surgical specimen).55,56 Since the decision to offer local ther-
apy with curative intent depends on predicting whether the Cancer Management and Research 2010:2 115
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tumor is organ-confined versus nonorgan-confined, the now 
famous “Partin tables” have profoundly influenced clinical 
practice. Of course, not all patients with pathologically organ-
confined disease relapse, and not all patients with pathologi-
cally organ-confined cancers are cured. Thus the importance 
of predicting surgical outcome using pre-surgical covariates 
was and remains uncertain.
Additional models have been developed to predict 
outcomes following radical prostatectomy or radiation 
therapy. Based on the work of D’Amico, a combination of 
pre-therapy PSA, Gleason score, and clinical stage can be 
used to stratify patients into low (T1–T2a, Gleason score 
2–6, and PSA 10 ng/mL), intermediate (T2b–T2c, Gleason 
score 7, or PSA 10–20 ng/mL), high (T3a or Gleason score 
8–10 or PSA 20 ng/mL), and locally advanced (T3b–T4) 
groups that predict risk for both biochemical recurrence 
and survival following definitive local therapy (radical 
prostatectomy or radiation).34,57,58 Similarly, Kattan et al have 
developed postoperative nomograms for predicting prostate 
cancer recurrence after radical prostatectomy.59,60 These 
tools not only help guide recommendations for individual 
patients, but also help stratify patients for clinical trials. For 
example, low-risk patients can be directed towards “active 
surveillance” trials, while high-risk patients can be direct 
towards adjuvant/neoadjuvant trials.
Despite the efforts detailed above, tumors with identical 
PSA and clinicopathologic characteristics often display 
biologic and clinical heterogeneity. For example, some 
low-risk tumors rapidly progress while some high-risk tumors 
are relatively indolent. Accurate stratification is particularly 
challenging for Gleason 7 tumors, the most commonly 
reported score. Gleason 7 cancers (ie, 3 + 4 or 4 + 3) repre-
sent a clinically heterogeneous group with variable biologic 
potential and clinical outcomes.61 Despite efforts to improve 
stratification of Gleason 7 tumors using PSA and clinical 
stage, it is clear the Gleason system is inherently limited by 
the ability of light microscopic methodology to distinguish 
tumors with different biologic potential.
Investigational approaches to improve risk stratification of 
localized disease include assessing suspicious nodes or small-
volume extracapsular extension by magnetic resonance imag-
ing (MRI) or positron emission tomography (PET), staging 
biopsies of seminal vesicles and extraprostatic tissue, and 
incorporation of molecular signatures derived from analysis 
of biopsy and/or prostatectomy specimens. For example, loss 
of tumor suppressor pathways (eg, p53) and gain of oncogene/
antiapoptotic pathways (eg, Bcl-2) contribute to prostate can-
cer progression.62,63 In addition to these and other “epithelial” 
events, the importance of the host-epithelial interaction in 
prostate cancer progression has been supported by evidence 
that pathways involved in paracrine regulation of normal 
stromal-epithelial interactions have also been implicated in 
prostate cancer progression.61,64,65 For example, sonic hedge-
hog and Src kinase signaling pathways are involved in normal 
bone development but their aberrant activation contributes 
to tumor progression. These pathways are currently being 
studied for biomarker development.
For patients with PSA-only recurrence after local therapy, 
PSA is commonly used as both a prognostic and predictive 
biomarker.39,66 The critical variable influencing therapy 
options for these patients is determining if the rise in PSA 
represents a local recurrence and/or microscopic metatastic 
disease. If patients are judged to have a local recurrence, 
salvage options are available, including radiation therapy after 
initial prostatectomy or cryosurgery after initial radiation 
therapy. For patients deemed to have micrometastatic disease, 
hormone ablative therapy is preferred. Both a rapid PSA 
velocity (rate of rise) and short PSA doubling time (PSADT) 
have been proposed as biomarkers to predict local versus dis-
tant metastases, and PSADT has additionally been predictive 
of risk for metastatic progression and cancer-specific mor-
tality.67–70 For patients who receive androgen ablation for 
PSA-only recurrent disease following local therapy with 
curative intent (surgery or radiation), PSA nadir is signifi-
cantly associated with prostate cancer-specific mortality.71 
At present, however, neither PSA velocity nor PSDAT have 
been prospectively validated, and there are still no established 
methods to accurately distinguish between local versus dis-
tant recurrence or to predict risk of metastatic progression 
and death in this patient group.
For patients with androgen-dependent metastatic 
disease, PSA nadir after androgen ablation is a strong pre-
dictor of overall survival, as is evidence for PSA progres-
sion after the nadir is achieved.72,73 Similarly, for patients 
with castrate resistant metastatic disease, the degree of 
PSA decline (eg, >50%) achieved with chemotherapy 
predicts overall survival benefit.74,75 Because PSA is an 
androgen-regulated gene, PSA decline may be a better 
biomarker for response to hormonal ablative therapies 
rather than cytotoxic chemotherapies. This is one of the 
reasons circulating tumor cells may prove superior to PSA 
as a biomarker in patients receiving cytotoxic therapy for 
castrate-resistant disease.5
Based on the above considerations, it is clear that novel 
biomarkers are needed in prostate cancer. PSA, considered 
alone or in combination with other clinicopathologic markers, Cancer Management and Research 2010:2 116
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has limitations as a biomarker and is not a valid surrogate 
for long-term benefit (ie, overall survival) in clinical trials 
testing novel therapies. Novel biomarkers will improve our 
ability to: distinguish clinically significant from insignificant 
cancers at diagnosis; predict which clinically significant 
tumors are at highest risk for relapse after local therapy so 
that adjuvant (or neoadjuvant) therapy can be applied; predict 
which patients with PSA-only relapse warrant aggressive 
therapy; predict response to therapies in the androgen-
  dependent and castrate-resistant disease states; and predict 
overall survival. Furthermore, in order to become useful in 
clinical practice, this biomarker should ideally be sensitive, 
specific, and reproducible.
Caveolin-1 in prostate cancer
Cav-1 is a major structural coat protein of caveolae, 
specialized plasma membrane invaginations involved in 
multiple cellular functions including molecular transport, 
cell adhesion, and signal transduction.76,77 Caveolae are 
normally expressed in highly differentiated cells including 
epithelial cells, endothelia, cardiomyocytes, adipocytes, 
and osteoblasts. Caveolae have a specialized structure 
and function that distinguish them from general plasma 
membranes, lipid rafts, or clathrin-coated pits.78 In 
particular, caveolae contain high concentrations of signaling 
molecules including G-proteins, receptor tyrosine kinases, 
non-receptor tyrosine kinases, and endothelial nitric oxide 
synthase (eNOS).79 These molecules interact with caveolae 
via protein-protein interactions with a 20-amino acid 
region of Cav-1 called the “caveolin-1 scaffolding domain” 
(CSD).80 Through CSD-mediated activities, caveolae act 
as compartments to organize signaling events from the 
cell surface to the inside of the cell and between specific 
intracellular organelles.81
Cav-1 was first implicated in cancer development when it 
was discovered to be a substrate for v-SRC in Rous sarcoma 
virus-transformed chicken embryo fibroblasts.82 Subsequent 
studies using both mouse and human cells revealed a complex 
role for Cav-1 in malignant transformation that is dependent 
on cell type, cell context, and growth conditions. For example, 
initial “gain of function” studies of Cav-1 ectopically 
expressed in breast cancer cells grown in vitro suggested 
that Cav-1 has tumor suppressor functions.83 Similar in vitro                                                                                                                                                                
studies also suggested a tumor suppressor role for Cav-1 in 
colon cancer and sarcoma cell lines.84 Cav-1 expression is also 
reduced in primary human breast cancers, colon cancers, and 
sarcomas, consistent with the notion that Cav-1 functions as 
a tumor suppressor in these tumor types.84
In contrast, immunohistochemistry analyses of primary 
human tumors of bladder, esophageal, breast, and prostate 
origin demonstrated aberrant overexpression of Cav-1 relative 
to normal tissues, suggesting an oncogenic role for Cav-1 for 
select tumor types.85–88 Importantly, immunohistochemical 
analysis of radical prostatectomy specimens obtained from 
patients with clinically localized tumors demonstrated that 
Cav-1 expression is positively associated with increasing 
Gleason grade, increasing Gleason score, lymph node 
involvement, and positive surgical margins.88 In a subset of 
lymph node-negative patients, multivariate analysis indicated 
that positive Cav-1 expression is an independent prognostic 
factor for a higher Gleason score (7), extraprostatic 
extension, seminal vesicle involvement, positive surgical 
margins, and shorter time to disease progression. In another 
study, patients with increased Cav-1 expression were at 
increased risk for developing an aggressive recurrence after 
surgery as defined by a PSADT of 10 months, failure to 
respond to salvage radiotherapy, and/or radiographically 
detected metastases.89 Taken together, these studies suggest 
that Cav-1 expression predicts development of prostate cancer 
with lethal potential.
In further support of this hypothesis, it is notable that 
Cav-1 was initially identified as a gene that is specifically 
upregulated in metastatic versus primary cancer cells in a 
mouse model system.87 Gain of function studies demonstrated 
that ectopically overexpressed Cav-1 protects prostate 
cancer cells from apoptotic stimuli.90 Loss of function 
studies demonstrated that Cav-1 antisense cDNA converts 
castrate-resistant mouse prostate cancer cells to an androgen-
dependent phenotype that is less prone to form metastases 
in vivo.91,92 As a corollary finding, selection for castrate-
resistant clones in vivo is associated with increased Cav-1 
levels. These studies demonstrate that Cav-1 independently 
promotes prostate cancer cell survival, clonal expansion, 
castrate-resistance, and metastatic activities.
The frequency of Cav-1 positive cancers also underscores 
its distinct functional role in malignant progression.87 In 
normal prostate tissues, Cav-1 is abundantly expressed in 
stromal smooth muscle and endothelial cells but minimally 
expressed in both ductal and acinar epithelium. In contrast, 
in clinically localized prostate cancer (T1/T2aN0), Cav-1 is 
focally expressed by malignant epithelial cells in ∼14% of 
cases. Cav-1 expression proportionally increases in high-grade 
primary tumors with lymph node metastases (T3N1; ∼30%) 
and in metastatic lymph nodes (∼56%). Increased Cav-1 
expression also correlates with hormone ablative therapy.93 
Analysis of primary tumor and metastatic specimens from Cancer Management and Research 2010:2 117
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patients with metastatic disease demonstrated that aberrant 
expression of Cav-1 was increased after hormone ablation in 
both primary (73% versus 38%) and metastatic (82% versus 
62%) sites. The focal expression of Cav-1 in primary prostate 
cancers, the increase in Cav-1 expression in untreated 
metastases, and the additional increase in Cav-1 expression 
in tumors treated with hormone ablative therapy support the 
hypothesis that Cav-1 functions in progression-related events 
rather than local tumor growth.
The mechanism(s) for increased expression of Cav-1 in 
aggressive prostate cancer remains unclear. Cav-1 is regulated 
by testosterone, but at relatively modest levels when com-
pared with PSA.92 This is evidenced by the relative paucity of 
Cav-1 expression in normal prostate acinar epithelium com-
pared with expression of PSA. Cav-1 is located on 7q31.1, a 
conserved fragile site that is frequently deleted and/or ampli-
fied in human cancers.94,95 In addition, the gene promoter 
for Cav-1 possesses a “CpG” island that has been reported 
to be hypermethylated, an event generally associated with 
transcriptional repression.96 However, Cav-1 expression levels 
do not consistently correlate with genetic and/or methylation 
changes of the Cav-1 gene.97 More recently, an alternative 
epigenetic mechanism for increased Cav-1 expression has 
been proposed through the aberrant, cancer-specific loss of 
miR-205, a noncoding microRNA that normally silences 
Cav-1 expression.98
To further explore the significance of Cav-1 overexpression 
in human cancer, numerous preclinical studies have been 
performed to elucidate the precise molecular mechanism(s) 
for Cav-1 mediated oncogenic activity. Caveolae modulate 
diverse intracellular signaling pathways involved in 
regulation of cellular proliferation, apoptosis, endocytosis, 
and cholesterol trafficking.12 This is principally achieved by 
the interaction of Cav-1 with a large number of molecules 
in either a CSD-dependent or CSD-independent manner. 
Notably, Cav-1 modulates the function of many classic 
oncogenes, including v-Src, H-ras, and C-neu.84 Cav-1 
inhibits or activates these pathways depending on the cell 
type and context.
In prostate cancer, Cav-1 interacts with and inhibits 
the serine/threonine protein phosphatases PP1 and PP2A 
in a CSD-dependent manner.90 PP1 and PP2A are two 
major classes of phosphatases that act as tumor suppressors 
by maintaining Akt in a dephosphorylated, inactive 
state. Cav-1-mediated inhibition of PP1 and PP2A results 
in constitutive activation of prosurvival Akt-signaling. This 
has important implications in understanding the biology 
of clinically significant prostate cancer, since activation 
of Akt contributes to the development of aggressive, 
castrate-resistant disease.99 In this manner, overexpression 
of Cav-1 represents an alternative to PTEN loss in activat-
ing Akt in prostate cancer. Inactivating mutations of PTEN, 
another major regulator of the (PI3-K)/Akt pathway, are also 
common in advanced prostate cancers.100
More recently, Cav-1 has been shown to participate in 
a reciprocal, positive feedback loop with multiple growth 
factors implicated in prostate cancer progression.101 Cav-1 
expression is increased in response to stimulation of prostate 
cancer cells by vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), fibroblast growth 
factor (FGF), and transforming growth factor β1 (TGF-β1). 
In turn, ectopic expression of Cav-1 increases expression of 
VEGF, TGF-1β, and FGF2 protein levels through stabilization 
of mRNA transcripts for these genes in an Akt-dependent 
manner. Functionally, these events increase the invasive 
properties of prostate cancer cell lines in vitro, a phenotype 
associated with enhanced metastatic potential in vivo.101 Addi-
tional studies showed that Cav-1 stimulates VEGF-mediated 
autophoshorylation of VEGF receptor 2 (VEGFR2) in both 
human prostate cancer cells and human umbilical vein endo-
thelial cells, illustrating the potential for Cav-1 to modulate 
angiogenesis through the cancer cell-host interaction.102
A major development in understanding Cav-1 biology 
was the discovery that Cav-1 is secreted by mouse and human 
prostate cancer cell lines.93 Phosphorylation of serine 80 in 
the CSD converts Cav-1 from an integral membrane protein 
to a secreted protein product.103 Cav-1 is then incorporated 
into other membrane-derived microvesicles that are secreted 
by prostate cancer cells, including “prostasomes” and 
“oncosomes”.104,105 Importantly, secreted Cav-1 confers 
growth-promoting and anti-apoptotic properties to cell lines 
lacking endogenous Cav-1.93 This effect is mediated through 
uptake of Cav-1 by the Cav-1-negative prostate cancer 
epithelial cells.14 In a preclinical orthotopic mouse model 
of prostate cancer, Cav-1 antibody suppressed growth and 
metastases of a Cav-1 secreting, castrate-resistant cancer cell 
line.93 These data indicate that secreted Cav-1 is a biologically 
active autocrine-paracrine factor that contributes to malignant 
progression and further suggest that Cav-1 is a valid therapy 
target.
In addition to its effects on prostate cancer epithelial cells, 
secreted Cav-1 also modulates the microenvironment in a 
manner that promotes tumor growth through neoangiogenesis. 
Comparison of wild-type and Cav-1 knockout mice show that 
Cav-1 (-/-) mice display an impaired angiogenic response 
to exogenous stimuli, including basic fibroblast growth Cancer Management and Research 2010:2 118
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factor (bFGF) and a murine melanoma cell line (B16F10).106 
Endothelial cells derived from Cav-1 knockout mice will 
internalize exogenous recombinant Cav-1 using lipid raft/
caveolae and clathrin-dependent endocytic pathways.14 
Internalization of exogenous Cav-1 by Cav-1 (-/-) endothelial 
cells significantly increases their in vitro proangiogenic 
activities including migration, nitrous oxide production, and 
tubule formation. In vivo, orthotopic implantation of Cav-1-
secreting mouse prostate cancer cells into mice demonstrated 
that tumors are both larger and more vascular in Cav-1 (+/+) 
versus Cav-1 (-/-) recipient hosts, although tumor-associ-
ated endothelial cells in Cav-1 (-/-) mice demonstrated 
uptake of tumor-derived Cav-1.14 In a second model system 
using a human prostate cancer cell line with inducible Cav-1 
expression, Cav-1 secreting tumors were both larger and more 
vascular than control tumors in nude mice.14
Correlative studies in primary human prostate cancers 
further substantiate a role for Cav-1 in promoting tumor-
associated neoangiogenesis. Analysis of 56 radical prosta-
tectomy specimens revealed that tumor microvessel densities 
(MVD) were significantly higher in Cav-1 positive than Cav-1 
negative tumors (based on Cav-1 scoring of tumor epithe-
lial cells).107 MVD is a measure of tumor angiogenesis and 
increased MVD is associated with higher pathologic stage 
and shorter time to disease progression in men undergoing 
radical prostatectomy for localized disease.108 Interestingly, 
the percentage of Cav-1 positive tumor-associated endothelial 
cells (TAECs) was also significantly increased in Cav-1 posi-
tive versus negative tumors. Quantitative analysis indicated 
that the percentage of microvessels containing VEGFR2-pos-
tive TAEC was higher in Cav-1 positive than Cav-1 negative 
tumors. Taken together, these positive correlations support 
the concept that Cav-1 promotes pathologic neoangiogenesis 
in human prostate cancer.
Initial studies have demonstrated that secreted Cav-1 
is a novel biomarker for predicting clinically significant 
prostate cancer. Secreted Cav-1 can be measured in periph-
eral blood using an ELISA that is sensitive, specific, and 
reproducible.13 The median serum Cav-1 level is significantly 
higher in patients with clinically localized prostate cancer 
than in men with benign prostatic hypertrophy or healthy 
controls.13 In a group of 419 patients undergoing radical 
prostatectomy for localized disease, patients with high 
preoperative serum Cav-1 levels had a 2.7-fold greater 
risk of experiencing a biochemical recurrence compared 
with patients with low values.109 In a subset analysis of 
patients with high-risk disease (PSA  10), those with high 
preoperative serum Cav-1 levels had a 2.4-fold greater risk 
of developing biochemical recurrence compared with those 
with low Cav-1 levels. Importantly, when both Cav-1 and 
biopsy Gleason score were combined into a multivariate Cox 
proportional hazard model, the analysis of both variables 
more accurately predicted for risk of biochemical recurrence 
than either variable alone. Lastly, Cav-1 could stratify patients 
with Gleason 7 tumors into high- and low-risk recurrence 
groups after adjusting for PSA levels.109
These data suggest that measurements of tissue Cav-1 
and serum Cav-1 expression levels represent clinically useful 
prognostic and predictive biomarkers for prostate cancer 
(see Table 1). In patients with localized disease at diagno-
sis, Cav-1 improves the ability of current predictive tools 
to distinguish patients with clinically significant disease 
from those with insignificant disease. In this way, serum 
and tissue Cav-1 levels supplement (rather than supplant) 
other established predictive variables including serum PSA, 
Gleason score, and clinical stage. Future research efforts 
will test whether Cav-1 expression levels identify patients 
with localized disease who would benefit from neoadjuvant 
and/or adjuvant therapy.
Notably, when compared with serum PSA, serum Cav-1 
more specifically identifies clinically aggressive disease. This 
likely reflects the fact that, unlike PSA, Cav-1 biologically 
contributes to malignant progression and the development 
of castrate-resistance. For the same reason, serum Cav-1 
measurement may also prove useful as a biomarker in other 
prostate cancer disease states (see Figure 1). For example, 
Table 1 Rationale for developing caveolin-1 as a biomarker for   
clinically significant prostate cancer
•    Cav-1 expression is significantly increased in prostate cancer versus 
normal epithelium.
•    Cav-1 expression is increased in metastatic versus localized prostate  
cancer.
•    In contrast with PSA, Cav-1 is an oncogene that significantly  
contributes to the biology of aggressive disease.
•  Prostate cancer cells secrete Cav-1 into the tumor microenvironment.
•    Like endogenous Cav-1, secreted Cav-1 promotes malignant  
progression through antiapoptotic activities, stimulation of 
angiogenesis, castrate-resistant growth, and metastases formation.
•    Secreted Cav-1 can be reliably and reproducibly measured from  
peripheral blood using a Cav-1-specific ELISA.
•    Serum Cav-1 levels are significantly higher in men with clinically  
localized prostate cancer than in men with BPH or healthy controls.
•    High pretreatment levels of serum Cav-1 predict for a shorter time  
to biochemical recurrence in patients undergoing radical 
prostatectomy for localized disease.
Abbreviations: BPH, benign prostatic hypertrophy; Cav-1, caveolin-1; ELISA, enzyme-
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in patients with PSA-only recurrent disease following local 
therapy, analysis of serum Cav-1 levels may help determine 
which of these patients warrant aggressive therapy. Similarly, 
in patients with castrate-resistant metastatic disease, serum 
Cav-1 levels may be useful in monitoring response to therapy. 
Since Cav-1 critically modulates both the epithelial and host 
tissue microenvironment, the success of novel treatment 
strategies that target both compartments should correlate 
with serum Cav-1 responses.
Summary
A growing body of preclinical and clinical data has 
established the importance of Cav-1 in the development of 
virulent prostate cancer. As an oncogene, Cav-1 protects 
prostate cancer epithelial cells from apoptotic stimuli, 
enhances prosurvival pathways mediated by multiple 
growth factors involved in prostate cancer progression, and 
supports castrate-resistant growth. Cav-1 also contributes 
to the metastatic potential of prostate cancer through 
induction of tumor-associated neoangiogenesis in the host 
microenvironment. Because it is a secreted protein that can be 
reliably measured in peripheral blood by ELISA, Cav-1 has 
enormous potential as a novel biomarker in prostate cancer. 
Preliminary studies suggest that serum Cav-1 enhances 
the performance of existing tools that rely on serum PSA, 
Gleason score, and clinical stage to predict outcomes for 
patients who receive treatment for localized disease. Serum 
Cav-1 should also prove useful as a prognostic/predictive 
biomarker for patients with PSA-only recurrent disease 
and in patients receiving therapy for metastatic disease. 
Additional studies are currently underway to validate this 
promising biomarker.
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